Yang W, et al. - In patients with type 2 diabetes mellitus (T2DM) inadequately controlled on basal insulin ±1 oral antidiabetic drug (OAD), researchers compared the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) administered three times daily (TID) vs twice daily (BID) in addition to metformin. Subjects were randomized to BIAsp 30 TID (n=220) or BIAsp 30 BID (n=217) for basal insulin and metformin ± 1 OAD. According to findings, BIAsp 30 administered either TID or metformin BID was a safe and effective option for treatment intensification in patients with T2DM after basal insulin failure and OADs. If HbA1c remains above target, if lunchtime meal is the largest meal of the day, or if persistent postprandial hyperglycemia is observed after lunch, it may be preferable to add the third injection at lunchtime.